217 related articles for article (PubMed ID: 10801874)
1. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine.
Onorato JM; Jenkins AJ; Thorpe SR; Baynes JW
J Biol Chem; 2000 Jul; 275(28):21177-84. PubMed ID: 10801874
[TBL] [Abstract][Full Text] [Related]
2. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications.
Metz TO; Alderson NL; Chachich ME; Thorpe SR; Baynes JW
J Biol Chem; 2003 Oct; 278(43):42012-9. PubMed ID: 12923193
[TBL] [Abstract][Full Text] [Related]
3. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications.
Metz TO; Alderson NL; Thorpe SR; Baynes JW
Arch Biochem Biophys; 2003 Nov; 419(1):41-9. PubMed ID: 14568007
[TBL] [Abstract][Full Text] [Related]
4. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation.
Voziyan PA; Metz TO; Baynes JW; Hudson BG
J Biol Chem; 2002 Feb; 277(5):3397-403. PubMed ID: 11729198
[TBL] [Abstract][Full Text] [Related]
5. Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions.
Requena JR; Fu MX; Ahmed MU; Jenkins AJ; Lyons TJ; Thorpe SR
Nephrol Dial Transplant; 1996; 11 Suppl 5():48-53. PubMed ID: 9044307
[TBL] [Abstract][Full Text] [Related]
6. Reaction of pyridoxamine with malondialdehyde: mechanism of inhibition of formation of advanced lipoxidation end-products.
Kang Z; Li H; Li G; Yin D
Amino Acids; 2006 Feb; 30(1):55-61. PubMed ID: 15990947
[TBL] [Abstract][Full Text] [Related]
7. Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions.
Voziyan PA; Khalifah RG; Thibaudeau C; Yildiz A; Jacob J; Serianni AS; Hudson BG
J Biol Chem; 2003 Nov; 278(47):46616-24. PubMed ID: 12975371
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation.
Miyata T; Ueda Y; Asahi K; Izuhara Y; Inagi R; Saito A; VAN Ypersele DE Strihou C; Kurokawa K
J Am Soc Nephrol; 2000 Sep; 11(9):1719-1725. PubMed ID: 10966497
[TBL] [Abstract][Full Text] [Related]
9. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats.
Alderson NL; Chachich ME; Youssef NN; Beattie RJ; Nachtigal M; Thorpe SR; Baynes JW
Kidney Int; 2003 Jun; 63(6):2123-33. PubMed ID: 12753299
[TBL] [Abstract][Full Text] [Related]
10. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes.
Stitt A; Gardiner TA; Alderson NL; Canning P; Frizzell N; Duffy N; Boyle C; Januszewski AS; Chachich M; Baynes JW; Thorpe SR
Diabetes; 2002 Sep; 51(9):2826-32. PubMed ID: 12196477
[TBL] [Abstract][Full Text] [Related]
11. Chelating activity of advanced glycation end-product inhibitors.
Price DL; Rhett PM; Thorpe SR; Baynes JW
J Biol Chem; 2001 Dec; 276(52):48967-72. PubMed ID: 11677237
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of a novel radical trapping and carbonyl group trapping anti-AGE agent: a pyridoxamine analogue for inhibiting advanced glycation (AGE) and lipoxidation (ALE) end products.
Culbertson SM; Enright GD; Ingold KU
Org Lett; 2003 Jul; 5(15):2659-62. PubMed ID: 12868883
[TBL] [Abstract][Full Text] [Related]
13. Glycoxidation and lipoxidation in atherogenesis.
Baynes JW; Thorpe SR
Free Radic Biol Med; 2000 Jun; 28(12):1708-16. PubMed ID: 10946212
[TBL] [Abstract][Full Text] [Related]
14. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.
Degenhardt TP; Alderson NL; Arrington DD; Beattie RJ; Basgen JM; Steffes MW; Thorpe SR; Baynes JW
Kidney Int; 2002 Mar; 61(3):939-50. PubMed ID: 11849448
[TBL] [Abstract][Full Text] [Related]
15. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions.
Fu MX; Requena JR; Jenkins AJ; Lyons TJ; Baynes JW; Thorpe SR
J Biol Chem; 1996 Apr; 271(17):9982-6. PubMed ID: 8626637
[TBL] [Abstract][Full Text] [Related]
16. Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal.
Nagaraj RH; Sarkar P; Mally A; Biemel KM; Lederer MO; Padayatti PS
Arch Biochem Biophys; 2002 Jun; 402(1):110-9. PubMed ID: 12051689
[TBL] [Abstract][Full Text] [Related]
17. Pyridoxamine prevents age-related aortic stiffening and vascular resistance in association with reduced collagen glycation.
Wu ET; Liang JT; Wu MS; Chang KC
Exp Gerontol; 2011 Jun; 46(6):482-8. PubMed ID: 21316441
[TBL] [Abstract][Full Text] [Related]
18. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage.
Voziyan PA; Hudson BG
Cell Mol Life Sci; 2005 Aug; 62(15):1671-81. PubMed ID: 15905958
[TBL] [Abstract][Full Text] [Related]
19. Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets.
Pamplona R; Dalfó E; Ayala V; Bellmunt MJ; Prat J; Ferrer I; Portero-Otín M
J Biol Chem; 2005 Jun; 280(22):21522-30. PubMed ID: 15799962
[TBL] [Abstract][Full Text] [Related]
20. Generation of protein carbonyls by glycoxidation and lipoxidation reactions with autoxidation products of ascorbic acid and polyunsaturated fatty acids.
Miyata T; Inagi R; Asahi K; Yamada Y; Horie K; Sakai H; Uchida K; Kurokawa K
FEBS Lett; 1998 Oct; 437(1-2):24-8. PubMed ID: 9804165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
